Though dasatinib has not been used in large clinical trials, including MDS/MPN diseases that are associated with CSF3R truncated mutations, it has shown a favorable outcome when used in a patient with B-cell acute lymphoblastic leukemia (ALL) associated with a CSF3R mutation. Here, CSF3R is linked to B-cell acute lymphoblastic leukemia.